OBJECTIVES

Adiposity rebound (AR), the childhood period at which body mass index (BMI) rises from its lowest point, is linked to increased risk of later obesity. The study aims to determine the average age at AR, describe baseline characteristics and analyze the correlation between these characteristics and timing of AR in a population of Filipino pediatric outpatients.

DESIGN

Seven subjects born between 2016 and 2019 from a University Hospital Outpatient Department participated in this cross-sectional analytic study. Childhood anthropometrics were retrospectively collected to determine the age at AR by plot visual inspection. Sex, birth weight and gestational age were obtained from hospital records; breastfeeding duration, maternal BMI, parental obesity, maternal age, maternal smoking, education, parity and family income were gathered through a questionnaire completed by mothers or guardians. Associations were assessed using bootstrap univariate linear regression.

RESULTS

The mean age at AR was 3.2 years (SD = 1.2). Vaginal delivery was significantly associated with later age at AR compared to cesarean section (p = 0.035). Socioeconomic status at ages 2 to 5 showed positive association with delayed AR. Higher monthly family income (≥₱19,000) at ages 2 to 5 years was significantly associated with delayed age at AR. Other baseline childhood and parental factors showed no significant correlation with age at AR.

CONCLUSION

These results highlight the complex and context-dependent nature of AR, emphasizing the need for further studies to better understand and mitigate early obesity risk in Filipino children.

Human ; Young Adult: 19-24 Yrs Old ; Universities ; Regression (psychology) ; Hospital Records ; Gestational Age ; Body Mass Index ; Obesity, Maternal

OBJECTIVES

In Asia, younger individuals (below age 45) are diagnosed to have type 2 diabetes with increased rates of obesity defined by lower BMI yet with greater visceral adiposity (waist circumference and waisthip ratios). The prevalence data on type 1 diabetes is not well established, considered to be low, but is seen to be increasing as well. This changing phenotype therefore, presents a clinical dilemma in terms of correctly classifying diabetes and deciding on the consequent appropriate treatment. Distinguishing type 1 from type 2 diabetes has become more difficult with type 2 diabetes dramatically increasing in young adults and children. This study aims to define the characteristics of diabetes among young adults in the Philippines to provide a basis for appropriate management amidst changes in diabetes phenotypes seen globally.

METHODS

In this cross-sectional analytic study, we characterized the demographic, metabolic, and autoimmune features of diabetes among young adult Filipinos aged 18 to 45 years old consulting at a tertiary referral center in Manila, Philippines. Baseline serum A1c, FBS, 75-g oral glucose tolerance test, insulin, serum C-peptide, insulin autoantibodies, leptin, adiponectin, lipid profile, and thyroid function tests were obtained from the participants and analyzed. The homeostasis model assessment (HOMA) was used to estimate the insulin sensitivity.

RESULTS

A total of 348 patients with diabetes were included, with females comprising two-thirds of the participants. The mean age at diagnosis of diabetes was 35.9±7.22 years. The mean BMI was 28.12 kg/m2, with median waist to hip ratio (WHR) of 0·93. Metabolic syndrome was found in 60% of participants and 67.82% were obese by body mass index. The mean A1c was 9.07±2.52%. Good glucose control (A1c less than 7.0%) was seen in 23% of participants  while nearly half (48%) had HbA1c which was >9.0%. The median levels of fasting insulin and C-peptide were 12.62 (range 1.33–90.42) mIU/L and 0.78 ng/mL (range 0–16.2), respectively. 

Included participants were diagnosed with diabetes within a year and as such, majority did not have any micro- or macrovascular complications. The most common diabetes complication was sensory neuropathy detected by monofilament testing, which was found in 28% of participants, followed by non-proliferative diabetic retinopathy in 13%. A history of previous diabetic ketoacidosis was found in 10 patients (2.87%). Glutamic acid decarboxylase (GAD) and insulin auto-antibodies were found in 3.2% and 19.3% of participants, respectively. Approximately half (51.73%) of the participants were insulin resistant by HOMA-IR.

CONCLUSION

In contrast with Caucasians and other Asians, diabetes among young Filipino adults is associated with lower BMI but with a similarly high visceral adiposity as shown by an elevated WHR. Metabolic syndrome with insulin resistance as defined by a variety of indices is predominant. Type 1 diabetes with autoantibodies occur in only a small fraction of this population. Data derived from this work can provide a framework for cluster analysis towards personalized management specific to this population.

Human ; Acids ; Adiponectin ; Adiposity ; Adult ; Aged ; Antibodies ; Asia ; Asian ; Asian Continental Ancestry Group ; Autoantibodies ; Body Mass Index ; C-peptide ; Carboxy-lyases ; Child ; Cluster Analysis ; Demography ; Diabetes Complications ; Diabetes Mellitus ; Diabetes Mellitus, Type 1 ; Diabetes Mellitus, Type 2 ; Diabetic Ketoacidosis ; Diabetic Retinopathy ; Diagnosis ; Fasting ; Female ; Glucose ; Glucose Tolerance Test ; Glutamate Decarboxylase ; Glutamic Acid ; Insulin ; Insulin Resistance ; Ketosis ; Leptin ; Lipids ; Metabolic Syndrome ; Obesity ; Patients ; Peptides ; Phenotype ; Philippines ; Population ; Prevalence ; Serum ; Therapeutics ; Thyroid Gland ; Thyroid Function Tests ; Young Adult

Abstract Background: This study aims to determine the effectiveness of programmed exercise with telerehabilitation at home in patients with obesity and knee osteoarthritis on visual analogue scale scores, body mass index, and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Methods: This research is a pre–post study in patients with obesity and knee osteoarthritis. Research subjects performed a series of exercise programs at home for 28 days. Before the program, there was an initial assessment from a psychologist and a nutritionist. During the program, there was tele-education, telemonitoring, and teleconsultation from doctors. Twenty-six female subjects participated. Results: Visual analogue scale scores decreased statistically significantly every week, until the end of the fourth week, compared with before the intervention (p<0.001). Body mass index and WOMAC scores decreased statistically significantly at the end of the fourth week compared with before the intervention (both p<0.001). Further analysis of all WOMAC components in the intervention group, including pain, stiffness, and physical function, also showed a statistically significant decrease (p<0.001). Conclusion: Programmed exercise as part of telerehabilitation at home has been statistically proven to reduce visual analogue scale scores, body mass index, and WOMAC in patients with obesity and knee osteoarthritis.
Telerehabilitation ; Knee Osteoarthritis ; Obesity ; Body Mass Index ; Visual Analogue Scale ; WOMAC

Introduction: Obesity is a complex metabolic condition associated with significant cardiometabolic risks. The Comprehensive Metabolic Therapy (CoMeT) programme is a multidisciplinary intervention designed to address these risks through integrated medical management, physiotherapy, and dietary counseling. This pilot study aimed to evaluate the effectiveness of the CoMeT programme on anthropometric, metabolic, and body composition parameters in adults with obesity. Methodology: We conducted a pilot pre–post study involving 11 adults with obesity (BMI ≥27.5 kg/m²) enrolled in the CoMeT programme at Hospital Putrajaya. Assessments at baseline and post-intervention included anthropometric measures (weight, BMI, waist circumference), metabolic parameters (hemoglobin A1c [HbA1c]), and body composition (skeletal muscle mass [SMM], body fat percentage) using InBody 970 bioelectrical impedance analysis. Data were analyzed using SPSS version 29.0. Results: The mean age was 38.5 ± 8.9 years, with baseline weight 134.7 ± 20.9 kg and BMI 49.8 ± 9.0 kg/m². Three participants defaulted follow-up, leaving eight for post-intervention analysis. The mean weight reduction was 2.1 ± 6.4 kg (1.6 ± 5.0%). Notably, the greatest reduction (−12.5%) occurred in a participant with high adherence to both the dietary and physiotherapy components of the intervention. Participants receiving GLP-1 receptor agonists (oral semaglutide) also demonstrated weight reduction (mean −2.5 kg). Conversely, weight gain was observed in some participants despite diet modifications, potentially due to low physiotherapy attendance or baseline metabolic factors. HbA1c improved modestly (−0.19 ± 0.29%). Body composition changes were minimal, with slight reductions in body fat percentage (−0.13 ± 1.2%) and SMM (−0.49 ± 1.88 kg). Conclusion The CoMeT programme shows promising early-stage effectiveness in improving anthropometric and metabolic outcomes with the greatest benefits observed in patients achieving high multidisciplinary adherence and adjunct pharmacotherapy. These findings highlight the potential of a multidisciplinary approach in managing high-grade obesity and emphasize the need for larger-scale studies to further validate these outcomes and optimize targeted lifestyle and therapeutic interventions
Body Composition ; Adult ; Obesity

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used in the management of type 2 diabetes mellitus (T2DM) and obesity because of their glucoselowering and weight reduction benefits. However, realworld outcomes may differ from clinical trial data. Methodology: This retrospective cohort study included adults with T2DM and obesity initiated on oral semaglutide or injectable dulaglutide at Hospital Sultan Haji Ahmad Shah between 2023 and 2025. Baseline and approximately 6-month follow-up data were obtained from electronic medical records. Outcomes included weight, body mass index (BMI), glycated hemoglobin A1c (HbA1c), total daily insulin dose (TDD), low-density lipoprotein (LDL), and gastrointestinal adverse effects. Results are presented as median (interquartile range, IQR). Results: A total of 22 patients were included, with a median age of 45 years (IQR 39.3–54.5); 13 (59.1%) were male. Thirteen patients (59.1%) received oral semaglutide and nine (40.9%) received injectable dulaglutide. In the semaglutide group, median HbA1c changed from 8.1% (7.4–9.1) to 8.2% (7.1– 9.3), weight from 95.4 kg (84.0–99.1) to 89.6 kg (79.0–100.0), BMI from 33.9 kg/m² (31.4–40.8) to 33.6 kg/m² (31.2–35.6), TDD from 64 IU/day (20–82) to 46 IU/day (18–48), and LDL from 2.2 mmol/L (1.6–2.3) to 2.3 mmol/L (1.3–3.0). In the dulaglutide group, median HbA1c improved from 7.6% (7.4–9.6) to 6.9% (6.5–8.4), weight from 117.0 kg (101.0–121.0) to 111.0 kg (105.0–119.0), BMI from 41.0 kg/ m² (40.0–49.0) to 42.5 kg/m² (38.0–48.0), TDD from 33 IU/ day (30.5–34.0) to 34 IU/day (30.5–34.0), and LDL from 2.2 mmol/L (1.8–2.9) to 2.6 mmol/L (2.0–4.0). Gastrointestinal side effects occurred in 4/13 (30.8%) oral semaglutide users and 0/9 dulaglutide users. Conclusion Injectable dulaglutide showed greater improvement in HbA1c, while both groups demonstrated variable effects on weight, BMI, insulin requirement, and LDL in routine practice.
Adult ; dulaglutide ; semaglutide ; Diabetes Mellitus, Type 2 ; Obesity

Introduction: Obesity is a chronic disease characterized by complex alterations in body composition and metabolic health. Traditional reliance on body weight may overlook important physiological adaptations during lifestyle intervention. Methodology: A cohort of 99 participants at programme entry underwent body composition assessment using bioelectrical impedance analysis. Parameters included percent body fat (PBF), visceral fat area (VFA), skeletal muscle index (SMI), and phase angle (PhA). Correlation analyses were performed to explore relationships between adiposity, muscle mass, and cellular health. Results: Participants demonstrated elevated adiposity (PBF 38.9 ± 8.9%; VFA 142.9 ± 56.1 cm²). PhA was inversely associated with VFA (r ≈ −0.23, p <0.05) and positively associated with SMI (r ≈ 0.49, p <0.001). Notably, a subset of overweight individuals exhibited relatively preserved PhA, indicating heterogeneity in metabolic health despite similar adiposity levels. Conclusion Body composition and PhA provide complementary insights into metabolic health beyond body weight. These findings support the role of bioimpedance-derived parameters in identifying metabolic heterogeneity and guiding personalized obesity management.
Body Composition ; Body Weight ; Workplace ; Obesity

Introduction: Semaglutide has shown clinically meaningful effects on weight and glycemic control in randomized trials, but realworld evidence from Malaysian public healthcare settings remains limited. Local data are particularly relevant because access to glucagon-like peptide-1 receptor agonists may be influenced by cost and availability. We evaluated the realworld effectiveness of once-weekly semaglutide in adults with obesity and type 2 diabetes mellitus (T2DM) managed in routine clinical practice at a Malaysian district hospital. Methodology: We conducted a retrospective observational study of adults with obesity and T2DM treated with once-weekly semaglutide at a single district hospital. Demographic, anthropometric, metabolic, and cardiovascular parameters were collected at baseline and follow-up. The primary outcomes were percentage weight change and the proportions of patients achieving at least 5% and at least 10% weight loss. Secondary outcomes included changes in body mass index (BMI), glycated hemoglobin A1c (HbA1c), blood pressure, lipid parameters, and insulin requirements. Paired analyses were performed to compare pre-treatment and post-treatment values. Results: Eight patients were included (mean age 45 years; 63% women; 88% Malay). All had T2DM and hypertension, while most had dyslipidemia. Mean baseline weight was 116.0 ± 22.7 kg, and mean BMI was 43.5 ± 9.0 kg/m². After a mean treatment duration of 23 months, mean weight decreased to 102.9 ± 23.8 kg, representing a mean reduction of 13.1 kg or 11.5%. Six patients (75%) achieved at least 5% weight loss, and four (50%) achieved at least 10% weight loss. Mean BMI decreased to 38.4 ± 8.4 kg/m². Mean HbA1c improved from 8.9 ± 1.9% to 6.3 ± 0.9%. Systolic and diastolic blood pressure declined from 153 ± 22 to 134 ± 17 mmHg and from 91 ± 17 to 82 ± 10 mmHg, respectively. Total cholesterol, low-density lipoprotein cholesterol, and triglycerides also improved. Among insulin-treated patients, all discontinued insulin during follow-up. No treatment discontinuations due to adverse effects were recorded. Conclusion In this small real-world cohort, semaglutide was associated with meaningful weight loss, improved glycemic control, favorable cardiometabolic changes, and successful insulin deintensification. These findings support its use in routine obesity-diabetes care, although larger prospective studies are needed.
Adult ; semaglutide ; Diabetes Mellitus, Type 2 ; Hospitals, District ; Obesity

Introduction: Polycystic ovarian syndrome (PCOS) is a complex endocrine disorder that significantly affects adolescent girls, particularly those with overweight or obesity. However, data examining the determinants and metabolic profiles of PCOS among adolescents with overweight and obesity remain limited, especially in Malaysia. This protocol describes a case-control study investigating the cardiometabolic, dietary, and psychosocial determinants of PCOS among adolescents with overweight and obesity. Methodology: This study is designed as a case-control study involving adolescent girls aged 13–16 years with a body mass index z-score >+1 standard deviation. Cases are defined as adolescent girls with a confirmed diagnosis of PCOS based on the recommendations of the 2017 International Consortium of Paediatric Endocrinology (ICPE), while controls are those who do not meet the diagnostic criteria for PCOS. A total sample size of 440 participants is required. Participants will be recruited from 22 secondary schools selected from a list of schools in Kuala Lumpur. Data on sociodemographic characteristics, psychosocial health, physical activity, and dietary intake will be collected using structured questionnaires. Blood samples will be obtained and analyzed for diagnostic testing (free testosterone), exclusion tests (thyroid-stimulating hormone, folliclestimulating hormone, luteinizing hormone, estradiol, prolactin, and dehydroepiandrosterone sulfate), and biochemical parameters (liver function tests, lipid profile, hemoglobin A1c, fasting glucose, fasting insulin, and inflammatory markers). Results: The study is expected to generate comprehensive data on the cardiometabolic, dietary, and psychosocial determinants of PCOS among adolescents with overweight and obesity. The findings will inform early screening strategies and targeted interventions aimed at reducing long-term reproductive and cardiometabolic complications. Conclusion This protocol outlines a structured approach to investigating PCOS in adolescence and addresses current gaps in early identification and risk stratification among highrisk populations.
Adolescent ; Humans ; Case-Control Studies ; Overweight ; Polycystic Ovary Syndrome ; Obesity

Introduction: While Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for weight reduction in type 2 diabetes mellitus (T2DM), interindividual variability exists. Lifestyle factors, particularly baseline physical activity, may modify weight loss outcomes. This study examined whether baseline activity influences GLP-1 RA efficacy in Malaysian patients. Methodology: A retrospective cohort of adults with obesity and T2DM receiving GLP-1 RAs (semaglutide or liraglutide) from January 2023 to December 2024 was analyzed. Baseline physical activity was classified as active or inactive. Primary outcomes were achievement of ≥3 and ≥5% weight loss over 6–12 months. Associations were assessed using Fisher’s exact test and logistic regression. Results: Among GLP-1-treated patients, those reporting baseline physical activity were more likely to achieve ≥3% weight loss and demonstrated trends toward higher, ≥5%, weight loss. Logistic regression suggested baseline activity increased the odds of clinically meaningful weight reduction, though statistical significance was limited by sample size. Conclusion Baseline physical activity may enhance GLP-1 receptor agonist-mediated weight loss in obese patients with T2DM. Integrating lifestyle interventions with pharmacotherapy may optimize treatment outcomes. Larger prospective studies are warranted to confirm these findings.
Humans ; Glucagon-Like Peptide-1 Receptor Agonists ; Exercise ; Weight Loss ; Obesity ; Diabetes Mellitus, Type 2

Introduction: Childhood obesity is associated with significant metabolic morbidity, particularly insulin resistance (IR) and metabolic syndrome. Acanthosis nigricans (AN) is frequently observed in children with obesity and may represent a practical clinical marker of IR. This study evaluated the association between AN, IR, and metabolic complications in paediatric obesity. Methodology: A retrospective review was performed of 148 children (88 males, 60 females; median age 12 years) attending the Paediatric Obesity Clinic at Universiti Malaya Medical Centre. Data included anthropometry, AN grading, family history, HOMA-IR, and metabolic screening. Outcomes assessed were dyslipidemia, metabolic-associated fatty liver disease (MAFLD), hypertension, obstructive sleep apnea syndrome (OSAS), and glucose dysregulation. Comparisons were made between children with and without AN at baseline and over follow-up (median 2.4 years). Results: AN was present in 81.8% of patients, and 82.4% had central obesity. Increasing AN grade was significantly associated with higher BMI SDS and American Academy of Paediatrics obesity class (p <0.05). AN was more prevalent among Malay and Indian children and was associated with a family history of obesity (p <0.05). Baseline metabolic abnormalities were common, including dyslipidemia (high triglycerides 31.8%, low HDL 30.4%, high LDL 29.7%), MAFLD (23.6%), OSAS (31.1%), and glucose dysregulation (27.7%), with no significant difference between groups. During follow-up, children with AN and more severe obesity developed significantly more metabolic complications, particularly MAFLD and OSAS, with increased requirement for non-invasive ventilation (p <0.05). Higher HOMA-IR was associated with glucose dysregulation but was not independently associated with AN. Conclusion AN is strongly associated with greater adiposity and predicts the progression of metabolic complications in children with obesity. Routine assessment of AN may help identify high-risk patients who would benefit from early, intensive intervention to reduce long-term cardiometabolic morbidity
Child ; Acanthosis Nigricans ; Biomarkers ; Obesity